Relmada Therapeutics Gains 6% On Positive Results Of REL-1017

Relmada Therapeutics, Inc. (RLMD) shares are rising more than 12 percent on Tuesday morning trading after the company reported positive results in phase 3 human abuse potential study of REL-1017 for the treatments of major depressive disorder or MDD.

The company said the study showed that all three doses of 25 mg, 75 mg and 150 mg tested in recreational opioid users, demonstrated a highly statistically significant difference against the active control drug, oxycodone 40 mg.

Currently, shares are at $26.58, up 6 percent from the previous close of $25.12.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT